McKesson Corporation (MCK) Stock Price & Analysis
McKesson Corporation (MCK) closed at USD 1,012.34 on Thursday, October 22, 2026, down 0.31% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 1,015.5; the Oct 22, 2026 session ranged USD 1,006.07–1,025 on volume of 629,443 shares. Market capitalization is $118.03B, with a 52-week range of USD 723.68–1,030.27 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:28 UTC.
Also available as compact Markdown for AI agents: nexqual.com/MCK.md
Key facts (MCK)
- Last four reported quarters (through Jun 30, 2026): revenue $411B, net income $4.59B (1.1% margin), free cash flow $6.42B (SEC filings).
- 1 of 80 tracked superinvestors hold MCK (13F, Q2 2026): 0 new, 0 added, 1 reduced, 0 unchanged.
- Total return with dividends: 1Y +28.2% vs S&P 500 +14.9%; 5Y +396.8% vs S&P 500 +80.3%.
- Next earnings: 2026-11-04, EPS estimate USD 10.75, revenue estimate $110B.
Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (MCK)
| USD | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $264B | $277B | $309B | $359B | $403B | $411B |
| Gross profit | $13.1B | $12.4B | $12.8B | $13.3B | $14.6B | — |
| Operating income | $2.04B | $4.38B | $3.91B | $4.42B | $6.21B | $6.50B |
| Net income | $1.11B | $3.56B | $3.00B | $3.29B | $4.76B | $4.59B |
| EPS (diluted) | $7.23 | $25.03 | $22.39 | $25.72 | $38.38 | — |
| Free cash flow | $4.05B | $4.77B | $3.88B | $5.55B | $5.72B | $6.42B |
| Gross margin | 5.0% | 4.5% | 4.2% | 3.7% | 3.6% | — |
| Operating margin | 0.8% | 1.6% | 1.3% | 1.2% | 1.5% | 1.6% |
| Net margin | 0.4% | 1.3% | 1.0% | 0.9% | 1.2% | 1.1% |
| Revenue growth | +10.8% | +4.8% | +11.7% | +16.2% | +12.4% | — |
| Cash + short-term investments | $3.53B | $4.68B | $4.58B | $5.69B | $3.98B | — |
| Total debt | $5.88B | $5.59B | $5.63B | $5.65B | $6.53B | — |
Fiscal years end Mar. EPS is split-adjusted.
Valuation (price ÷ last four quarters, through Jun 30, 2026) (MCK)
P/E at fiscal year-ends: Mar 2026 22.6x, Mar 2025 26.2x, Mar 2024 24.0x.
Superinvestors (SEC 13F-HR, Q2 2026) (MCK)
1 of 80 tracked investors hold MCK. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Stephen Mandel | Lone Pine Capital | 0.27% | $43.7M | Reduced -85.3% |
Analysts (MCK)
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-20 | Mizuho | Target raised | Neutral | $905 → $1020 |
| 2026-10-16 | UBS | Target raised | Buy | $1080 → $1200 |
| 2026-10-07 | Leerink Partners | Target raised | Outperform | $1030 → $1070 |
| 2026-09-14 | RBC Capital | Reiterated | Sector Perform | $845 |
| 2026-08-19 | Barclays | Target raised | Overweight | $925 → $1000 |
| 2026-08-19 | RBC Capital | Initiated | Sector Perform | $845 |
| 2026-08-11 | Wells Fargo | Target raised | Equal-Weight | $812 → $933 |
| 2026-08-06 | TD Cowen | Target raised | Buy | $989 → $1006 |
| 2026-08-06 | UBS | Target raised | Buy | $1050 → $1080 |
| 2026-08-06 | Evercore ISI Group | Target raised | Outperform | $860 → $1000 |
| 2026-07-24 | Citigroup | Target raised | Buy | $945 → $1000 |
| 2026-07-21 | TD Cowen | Target lowered | Buy | $1012 → $989 |
Total return (dividends reinvested) (MCK)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +28.2% | +396.8% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +28.3% | +37.7% |
| Volatility (annualized) | 30.4% | 24.3% |
| Max drawdown | -27.2% (Mar 2026→May 2026) | -25.4% (Feb 2026→May 2026) |
Companies that name MCK in their SEC reports
| Relationship to MCK | Company | Filing | Sentence |
|---|---|---|---|
| supplier | TAKEDA PHARMACEUTICAL CO LTD (TAK) | 20-F Jun 17, 2026 | “The sales to Cencora Group, McKesson Group and Cardinal Health Group were JPY 579,065 million, JPY 578,767 million and JPY 436,951 million, respectively, for the year ended March 31, 2024.” |
| customer | NextPlat Corp (NXPL) | 10-K Mar 31, 2026 | “Our primary supplier for the years ended December 31, 2025 and 2024 was McKesson.” |
| supplier | KAMADA LTD (KMDA) | 20-F Mar 11, 2026 | “For the year ended December 31, 2024, sales to our three largest customers, Kedrion, Takeda and McKesson, one of the largest U.S.-based” |
| supplier | SUPERNUS PHARMACEUTICALS, INC. (SUPN) | 10-K Mar 2, 2026 | “Each of our three major customers, Cencora, Inc., Cardinal Health, Inc., and McKesson Corporation, individually accounted for more than 15% of our total product revenue in 2025 and collectively accounted for more than 76% of our total product revenue in 2025.” |
| supplier | Amneal Pharmaceuticals, Inc. (AMRX) | 10-K Feb 27, 2026 | “For the year ended December 31, 2025, our four largest customers, Cencora, Inc., McKesson Drug Co., Cardinal Health, Inc., and CVS Health Corporation, collectively accounted for approximately 71% of our consolidated net revenue.” |
| supplier | BeOne Medicines Ltd. (ONC) | 10-K Feb 26, 2026 | “For the year ended December 31, 2025, sales to the Company's three largest product distributors, ASD Specialty Healthcare (Cencora), McKesson and Shanghai Pharmaceutical represented approximately 18.5%, 17.5% and 10.1% of product revenue, respectively, and collectively, represented approximately 37.1% of trade accounts receivable as of December 31, 2025.” |
| partner | Blackstone Secured Lending Fund (BXSL) | 10-K Feb 25, 2026 | “At Deloitte, Mr. Bass was responsible for all services provided to Forstmann Little and its portfolio companies and was the advisory partner for Blackstone, DIRECTV, 24 Hour Fitness, McKesson, IMG and CSC.” |
| customer | Medline Inc. (MDLN) | 10-K Feb 25, 2026 | “Additionally, other distributors of med-surg products similarly connect the fragmented supplier and provider bases and aggregate inventory from suppliers to deliver products to customers, such as McKesson, Cardinal Health, Owens & Minor, and Henry Schein.” |
| supplier | Merck & Co., Inc. (MRK) | 10-K Feb 24, 2026 | “The Company's customers with the largest accounts receivable balances are: McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., which represented approximately 22%, 21% and 13%, respectively, of total accounts receivable at December 31, 2025.” |
| supplier | Jazz Pharmaceuticals plc (JAZZ) | 10-K Feb 24, 2026 | “Defitelio is sold to hospital customers through subsidiary specialty distributors of McKesson.” |
| supplier | Bausch Health Companies Inc. (BHC) | 10-K Feb 19, 2026 | “The Company has Distribution Services Agreements ("DSAs") with several large wholesale customers such as McKesson Corporation, Cencora Inc., Cardinal Health, Inc. and McKesson Specialty.” |
| supplier | AMGEN INC (AMGN) | 10-K Feb 13, 2026 | “Our product sales to three large wholesalers, McKesson Corporation, Cencora, Inc. and Cardinal Health, Inc., each individually accounted for more than 10% of total revenues for each of the years 2025, 2024 and 2023.” |
| competitor | Cencora, Inc. (COR) | 10-K Nov 25, 2025 | “Our largest competitors are McKesson Corporation ("McKesson"), Cardinal Health, Inc. ("Cardinal"), and UPS Logistics, among others.” |
| supplier | Embecta Corp. (EMBC) | 10-K Nov 25, 2025 | “For example, for the fiscal year ended September 30, 2025, gross sales to Cencora, McKesson Corporation, and Cardinal Health, Embecta's three largest distributors, together represented approximately 42% of Embecta's worldwide gross sales.” |
MCK analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $10.75 | $10.75 | +0.0% | $109.95B | 15 |
| Next quarter (ends Dec 2026) | $10.94 | $11.03 | -0.8% | $113.21B | 15 |
| Current fiscal year (ends Mar 2027) | $44.66 | $44.26 | +0.9% | $431.85B | 16 |
| Next fiscal year (ends Mar 2028) | $50.63 | $50.33 | +0.6% | $461.42B | 16 |
Key Statistics (as of October 23, 2026 at 09:28 UTC)
| Price | USD 1,012.34 |
|---|---|
| Change | ▼ 0.31% (down) |
| Previous Close | USD 1,015.5 |
| Open | USD 1,025.62 |
| Day Range | USD 1,006.07 – 1,025 |
| 52-Week Range | USD 723.68 – 1,030.27 |
| Volume | 629,443 shares |
| Market Cap | $118.03B |
| Exchange | NYQ |
Technical Analysis (MCK)
Nexqual's technical model rates MCK "BUY" based on 5 bullish and 1 bearish signals across 127 daily candles, as of October 23, 2026 at 09:28 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 69.82 (neutral) |
| vs SMA50 | Above (USD 907.2) |
| MACD | 35.38 (positive) |
Earnings (MCK)
| Next Earnings Date | 2026-11-04 |
|---|---|
| EPS Estimate | USD 10.75 |
| Revenue Estimate | $109.95B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 9.93 vs est 9.54 ▲ beat |
| 2026-03-31 | USD 11.69 vs est 11.57 ▲ beat |
| 2025-12-31 | USD 9.34 vs est 9.27 ▲ beat |
| 2025-09-30 | USD 9.86 vs est 9.05 ▲ beat |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financials & Fundamentals (MCK)
| Total Revenue | $410.98B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +7.70% |
| Gross Margin | +3.63% |
| Operating Margin | +1.35% |
| Profit Margin | +1.12% |
| Current Ratio | 0.89 |
| Total Cash | $5.16B |
| Total Debt | $11.80B |
| Free Cash Flow (last four quarters to Jun 2026, SEC 10-Q / 10-K) | $6.42B (1.6% of revenue) |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Financial Health Score (MCK)
Nexqual rates McKesson Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:28 UTC.
| Growth | Solid — Revenue +12% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 4%, operating 1% (last 12 months) |
| Balance Sheet | Mixed — $5.16B cash and investments vs $9.73B debt (Jun 2026, SEC) |
| Cash Flow | Mixed — FCF $6.42B (last 4 quarters to Jun 2026, SEC), slim 1.6% margin |
| Efficiency | Mixed — No data |
Ownership (MCK)
| Insider Ownership | +0.05% |
|---|---|
| Institutional Ownership | +93.71% |
| Shares Outstanding | 116.59M |
| Float | 116.40M |
| Short % of Float | +1.96% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Leadership (MCK)
McKesson Corporation is led by Brian S. Tyler, CEO & Chairman, per Nexqual as of October 23, 2026 at 09:28 UTC.
| CEO & Chairman | Brian S. Tyler |
|---|---|
| Executive VP & CFO | Kenny K. Cheung |
| Senior Vice President of Corporate Finance, Investor Relations & Strategic Finance | Paula Adkison |
| Executive VP, Chief Information Officer & CTO | Francisco J. Fraga |
| Executive VP & Group President of North American Pharmaceutical Services | Kirk Kaminsky |
Major Backers & Investors (MCK)
Notable institutional backers of McKesson Corporation include Morgan Stanley, Franklin Resources, Inc., Massachusetts Financial Services Co., according to Nexqual as of October 23, 2026 at 09:28 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Morgan Stanley | 4.55% |
| Franklin Resources, Inc. | 2.49% |
| Massachusetts Financial Services Co. | 2.1% |
| FMR, LLC | 1.83% |
| JPMorgan | 1.5% |
| MFS SERIES TRUST I-MFS Value Fund | 1.34% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 9.26% |
| Vanguard Group | 9.2% |
| State Street | 4.91% |
| Geode Capital | 2.42% |
Source: Nexqual, October 23, 2026 at 09:28 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| COR | Cencora, Inc. | USD 338.48 | ▼ 0.57% |
| CAH | Cardinal Health, Inc. | USD 255.64 | ▼ 0.71% |
| HSIC | Henry Schein, Inc. | USD 86 | ▲ 1.16% |
| AHG | Akso Health Group | USD 1.22 | ▼ 3.94% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:28 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt